Arrowhead Pharmaceuticals (ARWR) Retained Earnings (2016 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Retained Earnings for 16 consecutive years, with -$1.6 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 38686.97% year-over-year to -$1.6 billion, compared with a TTM value of -$1.6 billion through Dec 2025, down 38686.97%, and an annual FY2025 reading of -$1.6 billion, down 34355.87% over the prior year.
- Retained Earnings was -$1.6 billion for Q4 2025 at Arrowhead Pharmaceuticals, up from -$1.6 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $5.4 million in Q2 2025 and bottomed at -$1.6 billion in Q3 2025.
- Average Retained Earnings over 5 years is -$552.5 million, with a median of -$276.2 million recorded in 2021.
- The sharpest move saw Retained Earnings crashed 1189400.0% in 2022, then skyrocketed 642.76% in 2025.
- Year by year, Retained Earnings stood at -$707.6 million in 2021, then fell by 21.84% to -$862.1 million in 2022, then crashed by 34.43% to -$1.2 billion in 2023, then soared by 100.36% to $4.1 million in 2024, then plummeted by 38686.97% to -$1.6 billion in 2025.
- Business Quant data shows Retained Earnings for ARWR at -$1.6 billion in Q4 2025, -$1.6 billion in Q3 2025, and $5.4 million in Q2 2025.